Yongde Luo
Overview
Explore the profile of Yongde Luo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
1337
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rao Z, Tang Y, Zhu J, Lu Z, Chen Z, Wang J, et al.
Nanomaterials (Basel)
. 2025 Mar;
15(5).
PMID: 40072149
Acute myocardial infarction, a leading cause of death globally, is often associated with cardiometabolic disorders such as atherosclerosis and metabolic syndrome. Metabolic treatment of these disorders can improve cardiac outcomes,...
2.
Guo Y, Bao Y, Chen Z, Rao Z, Luo Y, Ye S, et al.
Acta Biochim Biophys Sin (Shanghai)
. 2024 Dec;
PMID: 39719877
Fibroblast growth factor 21 (FGF21) plays a pivotal role in regulating metabolic processes and energy homeostasis, making it a promising therapeutic avenue for various obesity-related conditions. However, its therapeutic efficacy...
3.
Li X, Rao Z, Hu W, Lu W, Luo Y
Obes Rev
. 2024 Nov;
26(3):e13861.
PMID: 39546893
Metabolic dysfunction-associated steatohepatitis (MASH) is a condition characterized by hepatosteatosis, inflammation, and tissue damage, with steatosis as the initial stage, which involves chronic, excess deposition of lipids in hepatic lipid...
4.
Song L, Hou Y, Xu D, Dai X, Luo J, Liu Y, et al.
Cell Metab
. 2024 Oct;
37(1):104-120.e9.
PMID: 39393353
Bile acid (BA) homeostasis is vital for various physiological processes, whereas its disruption underlies cholestasis. The farnesoid X receptor (FXR) is a master regulator of BA homeostasis via the ileal...
5.
Huang Z, Pan T, Xu L, Shi L, Ma X, Zhou L, et al.
Acta Pharm Sin B
. 2024 Jun;
14(6):2791-2793.
PMID: 38828151
[This corrects the article DOI: 10.1016/j.apsb.2023.12.012.].
6.
Huang Z, Pan T, Xu L, Shi L, Ma X, Zhou L, et al.
Acta Pharm Sin B
. 2024 Apr;
14(4):1605-1623.
PMID: 38572102
Immune-mediated liver injury (ILI) is a condition where an aberrant immune response due to various triggers causes the destruction of hepatocytes. Fibroblast growth factor 4 (FGF4) was recently identified as...
7.
Ma J, Gong F, Kim E, Du J, Leung C, Song Q, et al.
Cancer Lett
. 2024 Feb;
586:216694.
PMID: 38307409
The KRAS mutation was believed to be locked in a GTP-bound form, rendering it fully active. However, recent studies have indicated that the presence of mutant KRAS alone is insufficient;...
8.
Li X, Lu W, Kharitonenkov A, Luo Y
J Intern Med
. 2024 Jan;
295(3):292-312.
PMID: 38212977
Human fibroblast growth factor 19 (FGF19, or FGF15 in rodents) plays a central role in controlling bile acid (BA) synthesis through a negative feedback mechanism. This process involves a postprandial...
9.
Lu W, Luo Y
Cancer Commun (Lond)
. 2023 Oct;
43(11):1267-1270.
PMID: 37803877
No abstract available.
10.
Zhou C, Pan X, Huang L, Wu T, Zhao T, Qi J, et al.
Biochim Biophys Acta Mol Basis Dis
. 2023 Sep;
1870(1):166870.
PMID: 37696161
Cholestasis is characterized by hepatic accumulation of cytotoxic bile acids (BAs), which often subsequently leads to liver injury, inflammation, fibrosis, and liver cirrhosis. Fibroblast growth factor 21 (FGF21) is a...